Clinical TopicsUncategorized

New combination drug treatment may successfully treat cystic fibrosis

Share

A combination of the drugs Kalydeco (ivacaftor) and lumacaftor, which has not yet been approved by the Food and Drug Administration (FDA), can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation (the most common form of the disease), according to two phase 3 clinical trials published in the New England Journal of Medicine. Read more.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Test Your Knowledge

What are the key elements to consider when creating a successful initial prompt for AI in nursing education?

Recent Posts